Increased Access for Better Care

Week in Review: Increased Access for Better Care

03.07.14 | By

Each patient is unique, which means that medicines and therapies often need to be tailored to fit individual needs to ensure the best possible care. While the research and development (R&D) pipeline holds the promise of new, innovative treatments for those suffering from a variety of diseases, it is important to explore all options to improve patient health.

This week, our own Dr. Bill Chin penned a guest blog post for Friends of Cancer Research, and participated in a panel discussion hosted by BioCenturyTV. The topic: Accelerating Medicines Partnership, or AMP. We launched AMP last month with the National Institutes of Health (NIH), 10 biopharmaceutical companies, and several non-profit disease foundations with the goal of finding new treatments in certain disease areas, while reducing the time and cost of their development. “If there’s anything we can do to keep patients from waiting another minute, another day, week, we should do it,” said Chin. It is this mindset that motivates organizations from across the health care ecosystem to combine their efforts and work together in hopes of reaching our common goal.

Developing innovative new treatments must go hand in hand with cultivating pathways that facilitate access to treatments once they reach the market. On Tuesday, President Obama released his budget plan for the 2015 fiscal year. Our President and CEO John Castellani noted that it could dismantle the Medicare Part D program, jeopardizing the health and livelihood of one of our nation’s most vulnerable populations.

Because Medicare Part D has been so successful and seniors are highly satisfied, there should be no reason to change the program. Earlier this year, the Centers for Medicare & Medicaid Services (CMS) proposed changes to the Six Protected Class Rule under Medicare Part D. The changes would not only limit plan options in certain areas but would also eliminate protections for several classes of medicines including antidepressants, immunosuppressants and potentially antipsychotics. In this week’s Conversations forum, John Castellani asked experts what these proposed changes would mean for patients. Read their responses and share your thoughts and personal stories on how this rule change could impact you or a loved one.

Don’t forget to check in with the Catalyst each week to see what new options we are exploring for patient wellness, and follow us on Twitter and Facebook for all updates and industry news in real-time. 



Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context